BPMC News

BeiGene, a Chinese biotech developing immunotherapies based on kinase inhibitors, announced terms for its IPO on Tuesday. The Beijing, China-based company plans to raise $126.5 million by offering 5.5 million ADSs at a price range of $22 to $24. Insiders intend to purchase 50% of the offering. At the midpoint of the proposed range, BeiGene would command a fully diluted market...read more

Yield IPOs yielded disappointing returns while biotech performance was anemic. 13 companies were added to the IPO calendar - including 7 in the health care sector - making this an inopportune week for a drop in the NASDAQ Composite. 49 companies have gone public in 2015, and average year-to-date...read more

Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, raised $147 million by offering 8.1 million shares (upsized from 7.2 million shares) at $18, above the range of $15 to $17. Blueprint Medicines plans to list on the NASDAQ under the symbol BPMC. Blueprint Medicines initially filed confidentially on 2/19/2015. Goldman Sachs and...read more

Up to six companies could price their IPOs this week. All are either LPs or health care companies (including three biotechs). Two LPs on deck, one offering power-generating wood pellets Enviva Partners LP (EVA) is backed by Riverstone/Carlyle and is the world’s largest...read more